CEO Clarke Atwell acknowledges that it’s not the first to bring topically-administered biologic therapies to the front of the eye

Claris Bio is seeking to address the need for therapies to treat corneal disease by developing recombinant human deleted hepatocyte growth factor to improve and accelerate corneal healing.

Meanwhile, Calliditas Therapeutics announced data from the proof-of-concept Phase II trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck.

Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues.

With the stakes raised, enter Kaan Certel, Omega’s new chief business officer who joined the team at the end of May, and is focused on forging new partnerships for the company.

The idea behind Aphaia Pharma is to treat metabolic disease early enough that patients don’t progress to a type 2 diabetes diagnosis.

At Tessera, we are building a broad toolkit of Gene Writers™ to therapeutically edit the genome. Our RNA Gene Writers are designed to efficiently introduce a range of genomic changes from small nucleotide substitutions to exon or gene-sized fragments using all‑RNA compositions.

Flagship and one of the companies it founded, ProFound Therapeutics, said today they’ve agreed to identify new obesity treatments in a collaboration with Pfizer.